Combining S-1 and Irinotecan for Advanced Gastric Cancer
Author Information
Author(s): Inokuchi M, Yamashita T, Yamada H, Kojima K, Ichikawa W, Nihei Z, Kawano T, Sugihara K
Primary Institution: Tokyo Medical and Dental University
Hypothesis
The study aims to determine the maximum-tolerated dose and efficacy of S-1 combined with irinotecan in patients with advanced gastric cancer.
Conclusion
The combination of S-1 and irinotecan is effective and well tolerated in patients with advanced gastric cancer.
Supporting Evidence
- The response rate was 62% among the patients treated.
- The median survival time for patients was 444 days.
- Severe toxicities were manageable and occurred in a minority of patients.
Takeaway
Doctors tested a new medicine combination to help people with stomach cancer, and it worked pretty well without causing too many problems.
Methodology
Patients received S-1 and irinotecan in a dose-escalation study to determine the maximum-tolerated dose and evaluate the treatment's effectiveness.
Limitations
The study was limited to a specific patient population and may not be generalizable to all patients with advanced gastric cancer.
Participant Demographics
Patients aged 20-80 years with unresectable locally advanced or metastatic gastric adenocarcinoma.
Statistical Information
Confidence Interval
95% confidence interval: 47.2–76.6%
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website